CAMP4 Therapeutics Corporation Diluted Shares Outstanding (Weighted Average)
CAMP4 Therapeutics Corporation (CAMP) reported Diluted Shares Outstanding (Weighted Average) of 57.93 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 57.93M shares, a 187.35% increase year-over-year.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 57.92M shares, a 187.42% increase year-over-year.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 53.86M shares, a 212.23% increase year-over-year.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 27.27M shares, a 4792.88% increase year-over-year.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for fiscal 2025 was 30.38M shares, a 547.76% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for fiscal 2024 was 4.69M shares, a 1087.44% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation weighted average number of shares outstanding, diluted for fiscal 2023 was 394.98K shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 57.93M shares 10-Q · filed 2026-08-13 | 57.93M shares 10-Q · filed 2026-08-13 | 56.57M shares derived: average of 3 quarters · filed 2026-08-13 | 49.25M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 57.92M shares 10-Q · filed 2026-05-07 | 55.89M shares derived: average of 2 quarters · filed 2026-05-07 | 46.35M shares derived: average of 3 quarters · filed 2026-05-07 | 39.80M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 53.86M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 40.57M shares derived: average of 2 quarters · filed 2026-03-05 | 33.76M shares derived: average of 3 quarters · filed 2026-08-13 | 30.38M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 27.27M shares 10-Q · filed 2025-11-06 | 23.72M shares derived: average of 2 quarters · filed 2026-08-13 | 22.55M shares 10-Q · filed 2025-11-06 | 21.21M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 20.16M shares 10-Q · filed 2026-08-13 | 20.16M shares 10-Q · filed 2026-08-13 | 19.19M shares derived: average of 3 quarters · filed 2026-08-13 | 14.53M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 20.15M shares 10-Q · filed 2026-05-07 | 18.70M shares derived: average of 2 quarters · filed 2026-05-07 | 12.65M shares derived: average of 3 quarters · filed 2026-05-07 | 9.61M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 17.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 8.90M shares derived: average of 2 quarters · filed 2026-03-05 | 6.10M shares derived: average of 3 quarters · filed 2026-03-05 | 4.69M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 557.44K shares 10-Q · filed 2025-11-06 | 520.54K shares derived: average of 2 quarters · filed 2025-11-06 | 503.45K shares 10-Q · filed 2025-11-06 | 484.68K shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 483.64K shares 10-Q · filed 2025-08-14 | 476.17K shares 10-Q · filed 2025-08-14 | 460.43K shares derived: average of 3 quarters · filed 2025-08-14 | 445.43K shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 468.69K shares 10-Q · filed 2025-05-13 | 448.82K shares derived: average of 2 quarters · filed 2025-05-13 | 432.69K shares derived: average of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | 428.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 414.69K shares derived: average of 2 quarters · filed 2025-03-27 | 394.98K shares 10-K · filed 2025-03-27 | |
| 2023-09-30 | 400.43K shares 10-Q · filed 2024-11-21 | 383.65K shares 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |